Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Medical transcription technology provider Abridge has emerged from stealth with seed and series A funding.

Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

University endowment-backed Will Ventures aims to unlock sports-related innovation across markets such as fitness, media and gaming.

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

McKesson Ventures was among the existing investors that provided $25m through a private placement that supported the deal between Augmedix and Malo Holdings.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Baidu-backed surgical telemedicine system developer Avail Medsystems notched up a series B round that hiked its overall funding to $125m.

The Novo-backed CAH therapy developer has set the range for an offering set to net it between $60m and $80m in proceeds.